– Data from a pooled dose group of participants initially enrolled in the multiple ascending dose portion of the trial to be compared against a matched natural history cohort – – Dyne also intends to provide the mean baseline value for video hand opening time (vHOT) in the ACHIEVE registrational expansion cohort (REC) in conjunction with these presentations – – Topline data from the ACHIEVE REC are on track for Q1 2027 – WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it will present additional one-year clinical data from the Phase 1/2 ACHIEVE trial of zeleciment basivarsen (z-basivarsen, also known...

HONG KONG, Sept. 08, 2026 (GLOBE NEWSWIRE) — 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3 E Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider, committed to becoming a next-generation artificial intelligence (“AI”) infrastructure solutions provider, today outlined its strategic initiatives regarding its “Full-Stack AI Storage Business Layout.” As multimodal large models become more prevalent, data throughput requirements are increasing. In response, the Company is coordinating its business lines spanning enterprise memory and storage modules, solid-state drives (“SSDs”), and all-flash storage servers, seeking to establish an integrated hardware platform for massive AI data processing scenarios. This initiative builds on the Company’s efforts over the past...

The planned device combines Bitcoin mining, DePIN connectivity and AI-assisted device management NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) — AGM Group Holdings Inc. (NASDAQ: AGMH, “AGM Group,” “AGM” or the “Company”), an integrated technology company specializing in high-performance hardware and computing equipment, today announced a joint project with HashBeaver, a digital computing infrastructure company, to develop a new desktop node for decentralized physical infrastructure networks (“DePIN”). The product is intended for use in homes and offices. It is expected to use a purpose-built application-specific integrated circuit (“ASIC”) to perform SHA-256 hashing for Bitcoin mining. Planned software features include device identification, remote management, operational data verification, mining-pool connectivity and artificial intelligence...

Seasoned financial services executive brings deep consumer lending and public markets expertise to advance Oportun’s mission and profitable growth. SAN MATEO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) — Oportun (Nasdaq: OPRT), a mission-driven financial services company, announced that Bill Franklin has joined the Company as Chief Financial Officer, effective today, September 8, 2026. Franklin will lead Oportun’s finance organization and partner with the executive leadership team to advance the Company’s financial strategy, operating discipline, and long-term value creation. “Bill brings an ideal combination of strategic finance leadership and deep consumer financial services experience, alongside a strong understanding of the public markets,” said Doug Bland, Chief Executive Officer of Oportun. “He is...

Vancouver, Canada, Sept. 08, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company” or “Clearmind”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced that the Yale University’s IRB has approved the initiation of patient recruitment for Parts B and C of its Phase I/II clinical trial evaluating CMND‑100. This approval advances the multicenter study, titled “A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND‑100 in Healthy Volunteers and Subjects with AUDand directly enables the Company to accelerate enrollment at Yale School of Medicine’s Department of Psychiatry. The Yale site...

Collaboration pairs SalesCloser’s AI sales agents with Tendril’s human-assisted outbound platform; each company will deploy the other’s solution and train its sales team on the combined offering VANCOUVER, BC, Sept. 08, 2026 (GLOBE NEWSWIRE) — SalesCloser Technologies Ltd. (“SalesCloser” or the “Company”) (TSXV: SCAI) (OTCQB: SCTLF) (FSE: MJ5), a pioneer in autonomous AI sales technology, today announces that it has entered into a collaboration agreement (the “Agreement”) dated September 7, 2026 with Tendril LLC (“Tendril”), a California-based sales acceleration company, to combine SalesCloser’s autonomous AI sales platform with Tendril’s human-assisted outbound dialing, nearshore staffing, and data-enrichment solutions. SalesCloser’s platform deploys AI-powered virtual sales agents that qualify inbound prospects, run product conversations,...

Establishes In-House AI Backbone at the Company’s Bridgeport, Connecticut Facility; Positions Quantum Cyber as an AI-Native, Vertically Integrated Autonomous Defense Manufacturer Norwalk, CT, Sept. 08, 2026 (GLOBE NEWSWIRE) — Quantum Cyber N.V. (Nasdaq: QUCY) (“Quantum Cyber” or the “Company”), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced that it has acquired a Lambda Hyperplane 8-A100 AI compute cluster, powered by eight NVIDIA A100 Tensor Core GPUs, to serve as the dedicated compute backbone for its Swarm Operating System and for the AI and autonomy features being built into Quantum Station, the Company’s battlefield command-and-control platform. The cluster is intended to be installed...

Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today provided a strategic update highlighting its transformation into a precision oncology-led biotechnology company, anchored by the advancement of CD228V, a second-generation CD228-targeted antibody-drug conjugate (“ADC”), while pursuing capital-efficient strategic partnerships to advance clinical development opportunities across its SkinJect® and Teverelix® Programs. CD228V now represents the principal...

Strategic actions reduce interest rate risk, provide greater liquidity for organic growth, improve balance sheet flexibility, and enhance overall earnings profile GREENVILLE, S.C., Sept. 08, 2026 (GLOBE NEWSWIRE) — United Community Banks, Inc. (NYSE: UCB) (“United” or the “Company”) today announced that, following the September 1 completion of the sale of Navitas Credit Corp. and NLFC Reinsurance Corp (collectively, “Navitas”), which netted the Company approximately $2.0 billion in proceeds, it has completed a strategic balance sheet repositioning of its investment securities portfolio. The repositioning is designed to reduce interest rate risk exposure, fund organic growth, and improve United’s future earnings profile by replacing lower-yielding investment securities with higher-yielding assets, while maintaining strong capital...